Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2015-11-13 Interim / Quarterly Rep…
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2015
2015-11-13 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 10, 2015, by Zafgen, Inc. It announces the company's financial results for the third quarter of 2015 and includes a press release as an exhibit. The text explicitly states that the press release is being furnished and incorporated by reference, and the document itself is a current report rather than a full financial report. The length is 2886 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report. The key phrase 'announced its financial results for the third quarter' and the inclusion of a press release as an exhibit strongly indicate this is an Earnings Release (ER) filing rather than a full Interim/Quarterly Report (IR). Therefore, the appropriate classification is Earnings Release (ER).
2015-11-10 English
FORM 4 SUBMISSION
Director's Dealing
2015-10-30 English
FORM 4 SUBMISSION
Director's Dealing
2015-10-30 English
SCHEDULE 13G
Major Shareholding Notification
2015-10-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the company announcing the closure of the randomized portion of clinical trials and references a press release as an exhibit. There are no financial statements or detailed financial data present. The document is primarily an announcement of an event rather than a full financial report or earnings release. Given the nature of the filing and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-10-22 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.